Is Petrelintide a Peptide? Amylin Analog Profile

Yes, and the clue sits in the last four letters of the name. Under World Health Organization International Nonproprietary Name conventions, the stem -tide is reserved for peptides and polypeptides, which means petrelintide was classified as a peptide before a single vial of it ever reached a clinical trial site.

We field this question weekly. Researchers read the name in a Roche announcement and can't tell from context whether they're looking at a small molecule, an antibody, or a peptide. It's a peptide: a lipidated, long-acting amylin analog.

Is petrelintide a peptide?

Yes. Petrelintide is a synthetic peptide, specifically a long-acting amylin analog developed by Zealand Pharma under the code ZP8396 and partnered with Roche in March 2025. It is built on the 37-amino-acid amylin scaffold, administered subcutaneously in trials, and studied with once-weekly administration.

The common mistake is filing petrelintide beside semaglutide and tirzepatide as one more incretin drug. It isn't. Amylin analogs act through a separate receptor family, which is why petrelintide has been studied both alone and in combination with an incretin rather than as a replacement for one. What follows covers its drug class and mechanism of action, what public sources do and don't specify about structure and molecular weight, and how the reported profile compares with pramlintide and cagrilintide.

Where petrelintide sits in the amylin drug class

Petrelintide is a long-acting amylin receptor agonist, and that single phrase answers the drug class question. Amylin, also called islet amyloid polypeptide or IAPP, is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells, and anything engineered to activate its receptors belongs to the amylin analog family. Petrelintide sits there. It is not a GLP-1 receptor agonist, not a GIP agonist, and not a dual incretin.

There is no petrelintide brand name, and there won't be one unless a regulator approves a finished product. Investigational compounds carry an INN plus a development code, and petrelintide carries ZP8396 from Zealand Pharma, the company that originated the molecule. In March 2025, Zealand Pharma and Roche announced a collaboration to co-develop petrelintide as a single agent and in fixed-dose combination with Roche's incretin candidate CT-388. That deal is why searches for petrelintide Roche now outnumber searches for the development code.

Pronunciation is simpler than it looks: pet-ruh-LIN-tide, four syllables, stress on the third. The internal -lin- borrows from amylin, and -tide flags the peptide chemistry, exactly as it does in pramlintide, cagrilintide, and semaglutide.

Our team has found that reading the INN stem first saves researchers a lot of guesswork. A name ending in -tide is a peptide. A name ending in -mab is a monoclonal antibody. Petrelintide is firmly in the first group, which also means it inherits the handling constraints of every synthetic peptide: aggregation risk, cold chain sensitivity, and the need to verify identity before anything enters a study.

How a long-acting amylin analog actually works

Amylin receptors aren't standalone proteins. Each one is the calcitonin receptor (CTR) paired with one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3, forming the AMY1, AMY2, and AMY3 complexes. The petrelintide mechanism of action described in the literature is agonism at those complexes, with activity concentrated in the area postrema of the hindbrain, a region outside the blood-brain barrier that reads circulating satiation signals. Downstream, amylin receptor activation slows gastric emptying, suppresses postprandial glucagon release, and promotes satiation through a pathway running parallel to GLP-1 signaling rather than through it.

Here's the part most summaries skip. The hard problem in building a weekly amylin analog was never receptor affinity. It was fibrillation. Human amylin is among the most amyloidogenic peptides in human physiology, it forms the islet amyloid deposits associated with type 2 diabetes, and its circulating half-life is roughly 13 minutes. Any analog expected to stay soluble in a vial for months and active in plasma for days has to be re-engineered for physical stability first. Zealand Pharma describes petrelintide as designed on that basis, with a lipid side chain supporting reversible albumin binding, the same half-life extension principle used in acylated incretin peptides.

That engineering is what produces the reported petrelintide half-life: multi-day rather than multi-minute, long enough that published trial designs used once-weekly subcutaneous administration. Public disclosures don't converge on a single figure, so the precise value belongs to the primary pharmacokinetic publication, not a secondary summary.

Is petrelintide oral? No. Every published clinical program has used the subcutaneous route, and no oral formulation appears in the public record. Petrelintide is investigational rather than an approved medicine, none of this is treatment information, and Real Peptides supplies research-use-only peptides to laboratories, never for human or veterinary use.

Structure, molecular weight, and the numbers nobody should guess

What's publicly known about petrelintide structure is qualitative: an analog of the 37-residue amylin sequence, modified to resist fibrillation, and lipidated for extended circulation. What isn't public, in the peer-reviewed literature at least, is the full amino acid sequence, the substitution positions, and the acylation site. Zealand Pharma's disclosures describe the design rationale without publishing a residue-by-residue map, so any page presenting a definitive petrelintide chemical structure diagram should be treated as unverified until it cites a primary source.

Molecular weight is the same situation with more confident-sounding guesswork around it. Native human amylin has a mass in the region of 3.9 kDa, and an acylated 37-residue analog would sit in a similar range, but public literature does not specify a confirmed petrelintide molecular weight or molecular formula. A mass figure is only useful when you can trace it to a certificate of analysis or a registered chemical identifier.

Which raises the practical point for anyone handling amylin-family peptides on the bench: this class aggregates. Sequence verification, HPLC purity data, and mass spectrometry confirmation matter more here than for a short, stable sequence, because a partially fibrillated amylin analog can look perfectly normal in a vial and behave erratically in an assay. Petrelintide is no exception to that chemistry. Our position on procurement is unglamorous and consistent across every compound we handle: confirm the identifier and the molecular identity against publicly verifiable analytical documentation before it enters a study. Real Peptides publishes certificates for its catalog compounds for exactly that reason, and produces every peptide through small-batch synthesis with exact amino-acid sequencing.

Petrelintide vs other amylin analogs: how the profiles compare

Amylin analogs differ mainly in how long they last and what had to be redesigned to buy that duration. The table below places petrelintide next to the native hormone and the two amylin analogs with the most public data behind them.

What If: Petrelintide Sourcing and Identity Scenarios

What if a supplier lists petrelintide as an oral product?

Treat the listing as a reason to request the full analytical package before anything else. Petrelintide has been studied by subcutaneous administration in every published program, and no oral formulation appears in the public record. Oral peptide delivery is technically achievable, as the tablet form of semaglutide shows, but it requires a permeation enhancer and a documented formulation development trail. A vendor claiming an oral version of a clinical-stage amylin analog without that trail is describing marketing copy, not chemistry.

What if the vial label reads ZP8396 and not petrelintide?

Record both identifiers, because they refer to the same molecule at different naming stages. ZP8396 is Zealand Pharma's development code, and petrelintide is the assigned International Nonproprietary Name, so literature published before INN assignment uses the code exclusively. Cross-searching both terms in PubMed and in trial registries is the only reliable way to retrieve the complete publication set, and missing the code-name papers is the most common reason a literature review on this compound looks thinner than it is.

What if a datasheet quotes a petrelintide molecular weight I can't verify?

Don't propagate the number. Public literature does not specify a confirmed petrelintide molecular weight or molecular formula, and a mass figure sitting on a product page with no certificate of analysis or registered chemical identifier behind it has zero traceability. For any peptide, the defensible practice is to check the claimed mass against the supplier's own mass spectrometry data rather than against an aggregator page that copied a figure from another aggregator page.

What if two papers report different half-life values?

Read the study design before trying to reconcile the figures. Half-life estimates shift with assay methodology, sampling window, single versus multiple ascending dose design, and whether the reported value is terminal or effective. For a lipidated peptide relying on albumin binding, apparent terminal half-life can also lengthen as exposure rises. Differences between disclosures are usually methodological rather than contradictory, which is why the design section matters more than the abstract here.

What if I need a long-acting amylin analog for a study right now?

Plan around availability instead of assuming it. Petrelintide is a proprietary clinical-stage asset held by Zealand Pharma and Roche, not a broadly catalogued research chemical, which is why most laboratories working on amylin signaling use published tool compounds or native amylin sequences instead. Whatever compound a study lands on, verifying identity and purity against publicly available analytical documentation before procurement is the step that protects the data set from an unexplained outlier six months later.

The Unflattering Truth About Amylin Analog Hype

Let's be direct about this: much of the excitement around amylin analogs is borrowed. Amylin receptor agonism is a genuine, well-characterised mechanism, and pramlintide demonstrated it in humans years ago, but the class earned its current attention largely from combination data with incretins rather than from standalone dominance. Anyone presenting petrelintide as a finished answer to metabolic disease is reading a press cycle, not an evidence package. It is a clinical-stage peptide with a credible design rationale and an incomplete public data set. Both halves of that sentence are true at the same time.

Researchers working with our catalog can review third-party analytical documentation on our certificates of analysis page, browse the full range in the peptide catalog, see which compounds are formatted for oral research use under oral research compounds, and check delivery coverage on our service coverage page. Every compound we supply is research use only.

Petrelintide answers its own identity question in its last four letters, but the more interesting fact is what those four letters cost to earn. Turning a hormone that self-assembles into amyloid within minutes into a molecule that stays soluble through a week of circulation is a protein-engineering result worth studying independently of whatever the clinical data eventually show. Mechanism was never the uncertainty in the amylin story. Stability was, and the distance between a 13-minute peptide and a weekly one is where the actual work happened.